Advanced in Clear Cell Sarcoma

Dr. Rhonda L. Bitting

Oncology | Hematology Oncology | Hematology
Medical Center Blvd Hematology And Oncology, 
Winston Salem, NC 
Advanced in Clear Cell Sarcoma
Medical Center Blvd Hematology And Oncology, 
Winston Salem, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rhonda Bitting is an Oncologist and a Hematologist Oncology provider in Winston Salem, North Carolina. Dr. Bitting is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. Her top areas of expertise are Prostate Cancer, Penile Cancer, Melanoma, Tissue Biopsy, and Prostatectomy.

Her clinical research consists of co-authoring 51 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Medical Center Blvd Hematology And Oncology, Winston Salem, NC 27157

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2 Double-blind, Placebo-controlled Study of the Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
A Phase 2 Double-blind, Placebo-controlled Study of the Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
Enrollment Status: Completed
Publish Date: September 30, 2025
Intervention Type: Other, Drug
Study Drug: Muscadine grape extract
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Drug, Radiation
Study Drugs: Apalutamide, Androgen deprivation, Docetaxel
Study Phase: Phase 2
Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma
Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Other, Drug, Biological
Study Drugs: Paclitaxel, Pembrolizumab
Study Phase: Phase 2
Correlation of Serum Catecholamine With Emotional Stress in Men With Prostate Cancer: A Pilot Study
Correlation of Serum Catecholamine With Emotional Stress in Men With Prostate Cancer: A Pilot Study
Enrollment Status: Completed
Publish Date: March 10, 2022
Intervention Type: Other, Procedure
Feasibility Study of a Home-Based Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Feasibility Study of a Home-Based Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)
Enrollment Status: Completed
Publish Date: April 20, 2021
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC)
Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC)
Enrollment Status: Completed
Publish Date: July 09, 2019
Intervention Type: Biological, Other
Study Phase: Phase 2
View 7 Less Clinical Trials

51 Total Publications

Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey.
Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey.
Journal: JCO precision oncology
Published: May 15, 2025
Similar Doctors
Timothy Collins
Distinguished in Clear Cell Sarcoma
Dr. Timothy Collins
Oncology | Hematology
Distinguished in Clear Cell Sarcoma
Dr. Timothy Collins
Oncology | Hematology

Novant Health Cancer Institute - Forsyth (Medical Oncology)

1010 Bethesda Court, 
Winston Salem, NC 
 (3.3 miles away)
336-277-8800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Timothy Collins is a Hematologist and an Oncologist in Winston Salem, North Carolina. Dr. Collins is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Familial Prostate Cancer, Adult Soft Tissue Sarcoma, and Nephrectomy.

Distinguished in Clear Cell Sarcoma
Dr. Christopher Y. Thomas
Hematology Oncology | Hematology | Oncology
Distinguished in Clear Cell Sarcoma
Dr. Christopher Y. Thomas
Hematology Oncology | Hematology | Oncology
Medical Center Blvd, 
Winston Salem, NC 
 (1.6 miles away)
336-716-2255
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christopher Thomas is a Hematologist Oncology specialist and a Hematologist in Winston Salem, North Carolina. Dr. Thomas is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Muscle Invasive Bladder Cancer, and Bone Marrow Aspiration. Dr. Thomas is currently accepting new patients.

Advanced in Clear Cell Sarcoma
Dr. Michael J. Mccormack
Hematology Oncology | Hematology | Oncology
Advanced in Clear Cell Sarcoma
Dr. Michael J. Mccormack
Hematology Oncology | Hematology | Oncology

Wake Forest University Health Sciences

Medical Ctr Blvd, 
Winston Salem, NC 
 (1.6 miles away)
336-716-2734
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Mccormack is a Hematologist Oncology specialist and a Hematologist in Winston Salem, North Carolina. Dr. Mccormack is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Non-Muscle Invasive Bladder Cancer. Dr. Mccormack is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bitting's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile